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Cardiovascular disease (CVD) remains the
greatest killer in the United States
(~ 700,000 deaths/year) and in most of the
Western world (1). Ischemic heart disease is
responsible for about two-thirds of the CVD
deaths in the United States. Arteriosclerotic
plaque is the arterial lesion most often asso-
ciated with ischemic heart disease.
Cigarette smoking is a major risk factor
for CVD (2) and is associated with > 25% of
the annual CVD deaths in the United
States. Environmental tobacco smoke (sec-
ond-hand smoke; ETS) also is recognized
now as a major contributing factor to CVD.
The American Heart Association has listed it
as a major pollutant and cardiovascular toxin
(3). Additionally, 40,000–60,000 excess
heart disease deaths are estimated to occur
yearly in the United States as a result of
long-term exposure to ETS (4,5). In cock-
erels, inhalation of environmentally relevant
levels of sidestream smoke, a surrogate for
ETS, produces statistically signiﬁcant accel-
eration of plaque development, even in the
absence of diets augmented with cholesterol
and/or saturated fats (6). Cockerels (6,7),
rabbits (8), and humans (3–5) all display
accelerated plaque development as a result of
chronic exposure to ETS. Similar findings
were reported recently for apo E-/-transgenic
female mice fed a high-fat diet while being
exposed to ETS (9).
Other in vivo studies demonstrated that
ETS tar, with its high concentration of poly-
cyclic aromatic hydrocarbons, has no effect
on plaque development and strongly sug-
gested that the plaque-promoting activity of
ETS, and likely of whole smoke as well,
resides in the vapor-phase (10). Inhalation of
1,3-butadiene, a “top 20” U.S. industrial
chemical and a prominent vapor phase com-
ponent of ETS (~400 µg/cigarette), produces
a profound, statistically significant increase
in plaque size (11). Other investigators have
focused recently on the vapor phase as the
major source of ETS toxicants contributing
to respiratory disease and lung cancer (12). 
Acrolein (CH2 = CH-CHO), a highly
reactive bifunctional aldehyde, is a ubiqui-
tous toxic air pollutant. Acrolein is used
widely in the chemical industry, especially in
the production of acrylic acid. About 0.9 bil-
lion pounds of acrolein are produced in the
United States each year (13). Acrolein also is
produced during incomplete combustion of
organic material and, like 1,3-butadiene, is a
prominent vapor-phase component of ETS.
About 1,200 µg of acrolein are present in the
ETS from just one moderate tar-ﬁltered cig-
arette, versus about 70 µg in the mainstream
smoke from the same cigarette (14). These
values are for the standardized, ﬁltered 1R4F
cigarettes [Tobacco and Health Research
Institute (THRI), University of Kentucky,
Lexington, KY], which we have used in our
previous studies (6,7).
Acrolein is the principal cytotoxic
metabolite of the anticancer and arthritis
drug cyclophosphamide and is the principal
and most physiologically active metabolite of
allylamine (15), which is metabolized intra-
cellularly to acrolein via semicarbazide sensi-
tive amine oxidase. The activity of this
enzyme is high in artery wall cells (16).
Allylamine has long been recognized as an
agent that elicits cardiotoxic and vasculo-
toxic responses. Avian artery smooth-muscle
cells are more sensitive to treatment with
allylamine and acrolein than are those of rat
artery. Among the reported changes are
reductions in cellular glutathione levels (17).
Pathologic alterations to the artery wall in
vivo and to artery wall cells in vitro after
treatment with allylamine or acrolein have
been reported (18) that are similar to
changes known to occur during develop-
ment of arteriosclerosis.
Acrolein is one of the most biologically
reactive of all the aldehydes. It has been
reported as a carcinogen [(19); see
“Discussion” below] and forms stable 1,N2-
propanodeoxyguanosine (acrolein-dG)–
DNA adducts (20,21), at least one of which
is mutagenic (22–25). 
Acrolein induces lipid peroxidation, pos-
sibly via metabolism to glutathionylpropi-
onaldehyde, which stimulates oxygen radical
formation (26). Peroxidized low-density
lipoprotein (LDL) is present in rabbit and
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Recent reports indicate that many of the cytotoxic and health-threatening components of envi-
ronmental tobacco smoke (ETS) reside in the vapor phase of the smoke. We have reported previ-
ously that inhalation of 1,3-butadiene, a prominent vapor phase component of ETS, accelerates
arteriosclerotic plaque development in cockerels. In this study we asked whether inhaled acrolein,
a reactive aldehyde that is also a prominent vapor-phase component of ETS, damages artery-wall
DNA and accelerates plaque development. Cockerels inhaled 0, 1, or 10 ppm acrolein mixed with
HEPA-ﬁltered air for 6 hr. Half were killed immediately (day 1 group) for detection of the stable,
premutagenic 1,N2-propanodeoxyguanosine acrolein adduct (AdG3) in aortic DNA via a 32P-
postlabeling/HPLC method, and half were killed after 10 days (day 10 group) for indirect assess-
ment of adduct repair. In the day 1 group, acrolein–DNA adducts were 5 times higher in the 1
and 10 ppm groups than in HEPA-filtered air controls. However, in the day 10 group, adduct
levels in the 1 and 10 ppm acrolein groups were reduced to the control adduct level. For the
plaque studies, cockerels inhaled 1 ppm acrolein (6 hr/day, 8 weeks), mixed with the same
HEPA-ﬁltered air inhaled by controls. Plaque development was measured blind by computerized
morphometry. Unlike butadiene inhalation, acrolein inhalation did not accelerate plaque develop-
ment. Thus, even though repeated exposure to acrolein alone has no effect on plaque size under
the exposure conditions described here, a single, brief inhalation exposure to acrolein elicits
repairable DNA damage to the artery wall. These results suggest that frequent exposure to ETS
may lead to persistent artery-wall DNA damage and thus provide sites on which other ETS
plaque accelerants can act. Key words: acrolein–DNA adducts, adduct repair, arteriosclerotic
plaque, environmental tobacco smoke. Environ Health Perspect 109:219–224 (2001). [Online
14 February 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p219-224penn/abstract.htmlhuman atherosclerotic plaques (27).
Oxidation of polyunsaturated fatty acids
associated with LDL also generates reactive
aldehydes (28). These, in turn, can modify
the protein (apo B) moiety of LDL, facilitat-
ing its uptake by macrophages and setting the
stage for the development of foam cell lesions
in the artery wall (29). Acrolein reactivity
with thiols, such as reduced glutathione (26)
and cysteine sulfhydryl groups, is largely
responsible for the potent protein cross-link-
ing potential of acrolein (30). Acrolein forms
protein adducts at the ε amino group of
lysine (e.g., in apo B of LDL) (29) and at the
imidazole nitrogen of histidine. Studies on
human plasma with vapor-phase cigarette
smoke aldehydes reveal that acrolein inhibits
the activity of lecithin-cholesterol acyltrans-
ferase, a key enzyme in reverse cholesterol
transport. Acrolein adduction of cysteine
sulfhydryls near the active site of this enzyme
has been implicated in the inhibitory effect of
acrolein. Acrolein may promote plaque devel-
opment by inhibiting reverse cholesterol
transport (31,32).
Autopsy studies of children and young
adults clearly show that plaque development
begins early in life (33–35). Thus, sensitive
individuals (e.g., children) exposed chroni-
cally to ETS may be at increased risk for
damage to arterial DNA, protein, and lipids
due to 1,3-butadiene and acrolein in ETS.
Several reports over the past 30 years have
implicated chemical carcinogens or viruses as
etiologic or major contributing factors to
plaque development in both humans and
animals, including avian models (36–41). 
The hypothesis we tested is that inhala-
tion of acrolein from ETS and other envi-
ronmental sources should increase the
likelihood that plaque will develop through
formation of stable premutagenic adducts in
artery wall cells. The experiments described
here focused on the connection between
inhalation exposure to environmentally rele-
vant levels of acrolein, acrolein–DNA
adduct formation in the aorta, and aortic
plaque development. We posed four ques-
tions: Are acrolein-specific DNA adducts
formed in arterial cell DNA after in vivo
exposure to environmentally relevant levels
of acrolein? Is there a dose dependence for
acrolein associated with adduct formation? Is
there evidence for repair of the acrolein-spe-
cific DNA adducts? And does extended
inhalation exposure to acrolein, at levels
comparable to those  found in ETS, acceler-
ate arteriosclerotic plaque development?
Materials and Methods
Animals. Four-week-old white leghorn cock-
erels (Avian Services, Frenchtown, NJ) were
quarantined for 2 weeks at New York
University’s (NYU) Nelson Institute of
Environmental Medicine Animal Facility in
Tuxedo, New York, before exposures began.
During this 2-week period they were accli-
mated to a 12-hr light/12-hr dark cycle and
observed for anomalous behavior and dis-
ease. They were housed in large stainless-
steel cages, and Association for Assessment
and Accreditation of Laboratory Animal
Care guidelines were followed for animal
housing and care. Food (Chick Starter
Grower; Purina, St. Louis, MO) and water
were available ad libitum except when the
cockerels were in the exposure chambers. All
experimental protocols were approved by the
Institutional Animal Care and Use
Committee of NYU Medical Center. 
Acute in vivo exposures. The general
exposure protocols described previously for
ETS and its components (6,7,11) were fol-
lowed here with acrolein. Exposures were
carried out in 1.3-m3 dynamic exposure
chambers at the Inhalation Facility of
NYU’s Nelson Institute of Environmental
Medicine. Twelve test cockerels were
exposed to 1 ppm acrolein (> 97% pure;
Sigma-Aldrich, St. Louis, MO) mixed with
HEPA-filtered air, while another 12 were
exposed to 10 ppm acrolein mixed with ﬁl-
tered air. Exposures were for 6 hr on 1 day.
Twelve control cockerels in adjoining cham-
bers were exposed to HEPA-filtered air
alone. There were 14 air changes/hr in each
chamber. Air was conditioned to maintain
the temperature in each chamber at 21°C.
Relative humidity was ambient.
Subchronic in vivo exposures. Eight cock-
erels were exposed to acrolein (> 97% pure;
Sigma-Aldrich) mixed with HEPA-filtered
air. Eight control cockerels in an adjacent
chamber were exposed simultaneously to
HEPA-ﬁltered air. The acrolein exposure level
selected for these studies was based on the
acrolein level in ETS produced during the
steady-state combustion of ﬁve ﬁltered 1R4F
reference cigarettes (THRI). A striking, statis-
tically signiﬁcant acceleration of plaque devel-
opment results from exposure to this level of
ETS (6). The chamber acrolein concentration
during this ETS study was 0.52 ppm. This
was the targeted steady-state acrolein level for
each chamber in the present acrolein study.
These subchronic acrolein exposures lasted 6
hr/day, 5 days/week, for 8 weeks. 
Steady-state chamber levels of acrolein
were monitored via an HPLC method (42).
Brieﬂy, we used cartridges of silica gel coated
with 2,4-dinitrophenylhydrazine for collec-
tion of acrolein and HPLC analysis of the
hydrazone derivatives. This method has been
used to measure levels of aldehydes, includ-
ing acrolein, in exposure chamber studies of
second-hand smoke (43). 
DNA purification. We extracted DNA
from individual abdominal aortas of half the
cockerels immediately following the 1-day
exposures to 1 ppm and 10 ppm acrolein. We
extracted aortic DNA from the other half of
the 1 ppm and 10 ppm acrolein-exposed
cockerels after sacriﬁce 10 days later to pro-
vide a measure of adduct repair. We isolated
aortic DNA from half the air control cock-
erels at each of these two time points as well.
Following humane sacriﬁce (Nembutal over-
dose), aortas were excised, cleaned, and frozen
in liquid nitrogen. They were stored at –80°C
until all samples were collected. Frozen tissue
in ice-cold Tris-EDTA (TE) buffer, pH 7.4,
was homogenized with a Tissuemizer
(Tekmar, Cincinnati, OH) and centrifuged to
collect the nuclear pellet. This was resus-
pended in TE buffer, digested (37°C, 30 min)
with RNase A and dialyzed RNase T1
(Sigma-Aldrich), followed by addition of
10% sodium dodecyl sulfate and proteinase K
for 30 min more. The sample was extracted
sequentially with freshly prepared TE-satu-
rated phenol, phenol/chloroform-isoamyl
alcohol (24:1), and chloroform-isoamyl alco-
hol. DNA was precipitated with 5M NaCl
and ice-cold ethanol, washed to remove traces
of salt, resuspended in 1.5 mM NaCl, 0.15
mM sodium citrate, and 0.1 mM disodium
EDTA and stored at –20°C. DNA purity was
assessed at 260/280 µm. Typical DNA yields
from the elastin- and collagen-rich aortas were
250–300 µg/g tissue. 
Plaque size measurements. We measured
plaque size as described previously
(6,7,10,11). Briefly, after Nembutal over-
dose of the cockerels, aortas were excised,
fixed in buffered formalin, cut into 5-mm
segments, embedded, sectioned, and stained
with hematoxylin and eosin. Plaque size
measurements on coded samples were made
blind, via computerized morphometry. The
PC-based BioQuant IV (R&M Biometrics,
Nashville, TN) software package was used to
quantitate plaque sizes. We measured sec-
tions from each of the six most distal (begin-
ning at the aortic bifurcation) segments from
each aorta because this is where the most
pronounced effects of environmental agents
on cockerel plaque size have been detected
(10). Plaque prevalence in the two groups
was compared by the chi-square test. For
each section, plaque cross-sectional area (if
plaque was visible) and the luminal circum-
ference were measured directly in triplicate.
We calculated plaque indexes (mean plaque
cross-sectional area [mm2]/mean luminal cir-
cumference [mm] × 100) from the means of
each triplicate determination for each of the
six distal aortic segments from each cockerel.
Prior studies have shown that plaque sizes
are log-normally distributed (6,7,10,11).
The skewed plaque sizes were log-trans-
formed for statistical evaluation. To analyze
plaque size by group, we plotted values on
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sion lines were calculated via least squares
analysis and drawn for each data set. We
used analysis of covariance to test for differ-
ences between the two regression lines. 
Detection and measurement of
acrolein–DNA adducts. The acrolein-DNA
adduct analysis (Figure 1) was carried out
via a 32P-postlabeling/HPLC method
(21,44). Briefly, the first step after
enzymatic hydrolysis of the DNA to 
3´-monophosphates was an HPLC prepu-
rification on a reversed-phase C18 column
(Burdick and Jackson, Baxter Healthcare,
McGaw Park, IL) with 1 mM Tris-HCl and
methanol:H2O (50:50) as buffer systems.
Fractions with retention times corresponding
to acrolein-specific adducts of deoxyguano-
sine were collected. Before 32P-postlabeling,
unmodified nucleotides were removed by
treatment with nuclease P1. Unlabeled
monophosphates were converted to labeled
3´,5´-bisphosphates by treatment with 32P-
ATP and T4 kinase. Adducted bisphosphates
were puriﬁed on thin-layer chromatography
(TLC) plates, excised, extracted, and recon-
stituted with distilled water. The sample was
spiked with authentic acrolein-speciﬁc stan-
dards as UV markers, and puriﬁed ﬁrst on a
reversed-phase system with 50 mM sodium
phosphate (pH 5.2) and methanol:H2O
(50:50) as buffer systems, and then on an
ion-pair HPLC system using 25 mM tri-
ethylamine phosphate and methanol:H2O
(1:1) as buffers. Finally, the purified
adducts were analyzed on a reversed-phase
HPLC system with 50 mM sodium phos-
phate (pH 5.8) and methanol:H2O (1:1) as
buffers with detection by a radioflow
detector. Co-migration of puriﬁed radiola-
beled adduct peaks obtained from aortic
DNA with the authentic UV standards was
considered confirmation of the identity of
the in vivo adducts (21,44,45). The method
is sufficiently sensitive to detect 1 nmol
adduct/mol guanine in DNA (44).
We determined statistically significant
differences (p < 0.05) in acrolein–DNA
adduct levels between acrolein-exposed and
air control cockerels in each data set by a
one-way analysis of variance with Dunnett’s
post-hoc test (46). 
Results
Identiﬁcation of acrolein–dG DNA adducts
in cockerel aortas. A typical HPLC chro-
matogram showing co-migration of the exo-
cyclic acrolein–dG adduct peak (UV and
radioactivity) from the synthetic standards
and from cockerel aorta DNA is shown in
Figure 2. The UV absorbance of the major
standard-AdG3, the acrolein-specific 1,N2-
propanodeoxyguanosine adduct, is shown in
(A). The UV absorbances of two croton-
aldehyde-specific adducts, CdG1 and
CdG2, for which we did not assay here,
also are shown in (A). The three rapidly
migrating peaks that appear before the
AdG3 peak in the standards were not identi-
fied. The radioactive peak representing
AdG3, the acrolein-speciﬁc adduct that was
isolated from cockerel aorta, is shown in (B).
Thus, the acrolein–DNA adduct, AdG3, is
formed in cockerel artery wall DNA after in
vivo exposure to acrolein.
Measurement of acrolein–dG adduct lev-
els in cockerel aortas. The target values for
the 1-day (6 hr) acute exposure studies were
1 ppm and 10 ppm, respectively. Steady-
state chamber concentrations of acrolein
were measured 5 times, at regular intervals,
during the 1 ppm exposures and 6 times
during the 10 ppm exposures. The actual
exposure concentrations (mean + SE) were
measured at 0.84 ± 0.27 ppm and 8.7 ± 0.79
ppm, respectively—in both cases about 15%
lower than predicted.
All cockerels in the two exposure groups
survived the single 6-hr exposures without
any apparent deleterious health effects,
according to observation of the animals and
gross inspection of internal organs at
necropsy. The exposure results (Figure 3)
reveal that a single 6-hr inhalation exposure
to a steady-state of 1 ppm acrolein in
HEPA-filtered air was sufficient to increase
acrolein–dG adduct levels in aortic DNA by
about 5 times over background levels. Adduct
levels in the 10 ppm group were slightly but
not significantly increased (p > 0.05) over
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Figure 1. Flow chart for acrolein–DNA adduct
analysis.
DNA digest + adduct 3’-monophosphates
Purification by reverse phase HPLC
Adduct 3’-monophosphate fractions
Adduct 3’,5’-bisphosphates
One-dimensional TLC
Identification and quantitation
by HPLC-radioflow detection
1. Nuclease P1 enrichment
2. [γ -32P] ATP, T4 Kinase
3. Apyrase
1. Autoradiogram
2. Extraction of adduct spots
Figure 2. Typical HPLC chromatograms showing co-migration of the single puriﬁed radioactive peak, cor-
responding to AdG3, the cyclic acrolein–dG adduct, from aortic DNA of an acrolein-exposed cockerel (B)
with AdG3 in the authentic UV standard (A). The peaks labeled CdG1 and CdG2 in (A) represent standards
for crotonaldehyde-speciﬁc DNA adducts, which were not investigated in this study. 
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is a dose dependence for acrolein associated
with adduct formation. However, acrolein
exposures in the parts per billion range
would have to be performed to conﬁrm this. 
Disappearance of acrolein–DNA adducts.
Ten days after the single 6-hr exposure to
either level of acrolein, adduct levels in
acrolein-exposed cockerels were reduced to
levels comparable to those in control cock-
erels (Figure 3). There were no differences (p
> 0.05) in adduct levels between the three
groups. Thus, there is evidence for repair of
the acrolein-speciﬁc DNA adducts.
Plaque development after semichronic
inhalation exposure to acrolein. On the basis
of the acrolein levels in an earlier ETS study
(6), we targeted the daily steady-state acrolein
concentration in the chambers for the 8-week
exposures here at 1 ppm. At this level, all the
cockerels survived the 8-week exposures
without any adverse health effects. Weight
gain over the 8-week exposure period was
similar in acrolein-exposed and air control
groups. At necropsy, internal organs were
grossly normal, with no apparent lesions. 
Plaque prevalence was similar for both
the 1 ppm acrolein-exposed and air control
groups. There were slightly more aortic seg-
ments with plaque in the air controls than
in the acrolein-exposed cockerels. However,
these differences were not statistically signif-
icant (chi-square test, α = 0.05; data not
presented). The log-normally distributed
plaque sizes were plotted versus cumulative
percentage of plaque-containing segments
on log-probability coordinates, as described
previously (6,7,10,11) (Figure 4). The linear
regression lines drawn for each set of values
had nearly identical slopes, and there were no
signiﬁcant differences in plaque size between
the two groups. Thus, in the absence of other
toxicants, 8 weeks of daily (6 hr/day) expo-
sure to 1 ppm acrolein, a moderately high
(47) but still environmentally relevant dose,
are insufﬁcient to accelerate plaque develop-
ment in a sensitive animal model.
Discussion
Five new ﬁndings emerge from the data pre-
sented in Figures 2–4. First, the acrolein-
specific, 1,N2-propanodeoxyguanosine
adduct, AdG3, has been identified for the
first time in vascular tissue. Although the
experiments here were not designed to iden-
tify the site of acrolein–dG adduct forma-
tion, there is clear evidence that acrolein is
metabolized by both avian and rodent arter-
ial cells in vivo (18). Thus, it is reasonable to
conclude that long-term exposure to acrolein
or to mixtures containing high concentra-
tions of acrolein, such as ETS, will damage
vascular wall DNA. Previous studies with
mammalian samples have identified three
acrolein–DNA adducts. Of the three, AdG3
was the major adduct found in human tis-
sues (44) and was the only one detected in
this study. This may reflect a difference
between avian and mammalian metabolism
or might represent a tissue-speciﬁc response. 
Second, the results suggest a dose
response for adduct formation resulting
from inhaled acrolein, and, if anything,
they overestimate the acrolein levels neces-
sary to elicit damage to vascular wall DNA.
Because the mean adduct levels are both
elevated and so similar in the 1 ppm and 10
ppm groups (Figure 3), the results strongly
suggest that high adduct levels would be
registered at acrolein levels even below 1
ppm. Although a single 6-hr exposure to 10
ppm acrolein produced no obvious adverse
health effects on the cockerels, 6-hr expo-
sures to 5 and 10 ppm acrolein for 3 con-
secutive days caused significant morbidity
and mortality, respectively (data not pre-
sented). Thus, at least in cockerels, 1 ppm
acrolein is below the threshold for systemic
toxicity as well as sufficient for DNA
adduct formation.
In an earlier ETS study (6), the steady-
state ETS from ﬁve cigarettes was distributed
to four chambers, each with seven or eight
cockerels. The acrolein concentration per
chamber in that study was 0.52 ppm. The
target acrolein chamber concentrations in
the studies reported here were only 2–20
times higher than that, and the measured
concentrations were 1.65–16.5 times higher.
Thus, these results strongly suggest that sig-
niﬁcantly elevated acrolein–dG levels will be
produced and retained in artery-wall DNA
within 1 day of exposure to environmentally
relevant levels of ETS.
Third, the strikingly lower levels of
AdG3 at 10 days compared to those at 1 day
(Figure 3) are consistent with repair of the
acrolein-induced DNA damage. Repair was
not measured directly. However, cockerels in
the 1-day and 10-day groups were exposed
simultaneously, in the same set of chambers,
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Figure 3. Levels of AdG3, the acrolein–dG adduct,
in aortic DNA from acrolein-exposed cockerels
on day 1 and day 10 after single 6-hr inhalation
exposures to 1 ppm and 10 ppm acrolein. Values
are expressed as a percentage of the respective
control values at day 1 and day 10.
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Figure 4. Log-normal distribution of plaque sizes. Plaque indexes (PIs) are plotted versus probit units
(lower abscissa) and cumulative percentage of plaque-containing segments (upper abscissa) on log
probability coordinates. Linear regression lines calculated via least squares analysis were drawn for each
data set. Thirty-two plaque index values are represented on the lower line, and 24 plaque index values are
represented on the upper line. The two lines have nearly identical slopes, and there were no signiﬁcant
differences between plaque size distributions in the two groups.
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1 ppm acroleinto the acrolein. The striking, statistically sig-
niﬁcant increases in aortic DNA adduct lev-
els in the 1 ppm and 10 ppm groups
compared to controls, which was evident in
tissues harvested 6 hr after acrolein exposures
ended, contrast strongly with the similarity
in adduct levels among the three groups after
10 days. These results imply that the damage
to aortic DNA represented by the AdG3
adduct was repaired in situ during the 9 days
between exposure and sacrifice. Another
interpretation of these 10-day results also
should be considered: that they are caused,
at least in part, by cell death. Large-scale
necrosis is likely not involved, because the
results from the 8-week exposures revealed
no apparent histologic differences between
acrolein-exposed and air control cockerels.
However, apoptosis in response to the initial
acrolein exposure followed by a compen-
satory cell proliferation also might explain
the apparent repair at 10 days and the lack
of obvious histologic differences after 8
weeks. Regardless of whether repair of DNA
damage or cell death and subsequent prolif-
eration best explains our results, the data
indicate that transient exposure to even rela-
tively high levels of acrolein, in the absence
of concomitant exposure to other genotoxic
agents, will not have long-term genotoxic
effects, at least in this animal model.
Fourth, the increased acrolein–dG
adduct levels in cockerel aorta DNA in vivo
confirm and extend earlier in vitro findings
that avian artery wall cells are more sensitive
to treatment with acrolein, or its precursor
allylamine, than are rat artery cells (17).
This is consistent with what is known about
susceptibility of animal models to environ-
mentally associated cardiovascular disease.
Rat arteries are generally refractory to
plaque development, but cockerel arteries
are not. Cockerels also are the only animals
besides humans in whom exposure-related
acrolein–dG adducts have been identified
thus far. The one published study of humans
reported elevated acrolein–dG adduct levels
in the oral tissue of long-term cigarette
smokers compared to controls (45). In ear-
lier studies, the low but measurable back-
ground level of acrolein–dG adducts in both
rodent and human tissues were attributed to
endogenous lipid peroxidation (21,44). This
likely explains the background levels of
acrolein–dG adducts in cockerels as well. 
The fifth finding (Figure 4) was that 8
weeks of daily (6 hr/day) exposure to 1 ppm
acrolein had no effect on plaque develop-
ment in a model system that is very sensitive
to the plaque-modulating effects of a variety
of chemicals and complex mixtures
(6,11,38). The acrolein–dG adduct levels in
the cockerel abdominal aortas were not mea-
sured after the 8 weeks of acrolein exposure
because all the tissues were taken for mor-
phometric analysis. However, given the
results following the 1-day acrolein expo-
sures, it is reasonable to assume that after 8
weeks of daily acrolein exposure, artery-wall
DNA-adduct levels would, if anything, be
higher than those found after 1 day. Thus,
the presence of the DNA damage repre-
sented by the acrolein–dG adducts is by
itself insufﬁcient to augment plaque develop-
ment. Although these results were disap-
pointing, they were not totally unexpected.
In a report describing acrolein carcino-
genicity noted above (19), acrolein treat-
ment (2 times/week, 6 weeks, followed by
uracil feeding) yielded greater numbers of
papillomas than were seen in controls. No
carcinomas were observed. In the absence of
uracil feeding, no increases in papilloma
numbers were observed. Thus, by itself
acrolein is a weak carcinogen. Acrolein-asso-
ciated DNA damage was not investigated in
that study. Although the mutagenicity of
acrolein is well established, our results indi-
cate that, at least in vivo, acrolein-associated
DNA damage alone is insufficient to elicit
long-term adverse health effects in the artery
wall. These results suggest that frequent
exposure to ETS may lead to persistent
artery-wall DNA damage from the acrolein
component of ETS and thus provide sites on
which other ETS plaque accelerants, such as
1,3-butadiene, can act. In support, a recent
report showed that acrolein alone was not
nearly as effective as cigarette smoke, which
is known to contain a number of potential
DNA damaging agents, at inducing DNA
damage in human lymphoid cells (48). The
need for additional DNA damage to aug-
ment that provided by acrolein–dG forma-
tion was shown in an earlier study where
acrolein was mutagenic to fibroblasts from
xeroderma pigmentosum patients but not to
fibroblasts from healthy controls (49). The
mutagenic responses and possible health
effects arising from combined in vivo admin-
istration of acrolein and other selected ETS
components, such as 1,3-butadiene, should
be investigated. 
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